Serum carboxypeptidase activity and genotype-stratified CA19-9 to detect early-stage pancreatic cancer
Clinical Gastroenterology and Hepatology Oct 15, 2021
Tanaka H, Tamura K, Abe T, et al. - Findings demonstrate diagnostic utility of serum carboxypeptidase A (CPA) activity prior to the emergence of pancreatic atrophy as a marker of localized pancreatic ductal adenocarcinoma (PDAC), including Stage I disease.
This study involved 345 controls receiving pancreatic surveillance and 190 patients with resectable PDAC.
Among controls, significantly higher serum CPA levels were detected in those having one or more minor alleles of CPA1 variants rs6955723 or rs2284682 relative to those without.
Elevated CPA was not detected in any of the PDAC cases with pancreatic atrophy.
In 122 PDAC cases with no atrophy: serum CPA diagnostic cut-offs defined by a person’s CPA1 variants, afforded a diagnostic sensitivity of 18% at 99% specificity (vs 11.1% sensitivity via a uniform diagnostic cut-off); integrating CPA with variant-stratified CA19-9 offered a sensitivity of 68.0% vs 63.1% for CA19-9 alone; among Stage I PDAC cases, diagnostic sensitivity was 51.9%, vs 37.0% for CA19-9 alone.
A specificity of 98.2% was conferred by the variant-stratified diagnostic cut-off, in the validation control set.
Exclusive Write-ups & Webinars by KOLs
Daily Quiz by specialty
Paid Market Research Surveys
Case discussions, News & Journals' summaries